Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Acadia Pharmaceuticals (ACAD) PT Lowered to $16 at Stifel
November 3, 2022 11:19 AM EDTStifel analyst Paul Matteis lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $16.00 (from $17.00) while maintaining a Hold rating.
The analyst commented, "We are reiterating our Hold rating on ACAD following yesterday's 3Q22 update. Nuplazid missed for the quarter ($130.7MM vs. $139.9MM), as... More
